SPLITOAK STRATEGIES LLC for ALKERMES, INC.
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Medicare/Medicaid MMM
Maintain access to mental health medications for the low-income subsidy (LIS) eligible population under Medicare Part D in prescription drug reform legislation (S. 2543, Prescription Drug Pricing Reduction Act; H.R. 3, Lower Drug Costs Now Act)
| Lobbyist | Covered position, as disclosed |
|---|---|
| SARAH KUEHL EGGE | — |
Alcohol and Drug Abuse ALC
Advance the use and funding of FDA-approved medicines to treat addiction in criminal justice and public health settings; FY2020 appropriations for Labor-HHS, CJS and Interior (Indian Health Service) bills
| Lobbyist | Covered position, as disclosed |
|---|---|
| SARAH KUEHL EGGE | 1998-2000 Legislative Assistant to Senator Bob Kerrey; 2001-2012 Senior Budget Analyst for Senate Budget Committee (Kent Conrad); Fall 2011, Deputy Staff Director, Joint Select Committee on Deficit Reduction |
Health Issues HCR
Awareness of the need for access to all FDA-approved medications Support patient-centered care and treatment that ensures comprehensive care and access to all FDA approved treatments Initiatives to promote the use of relapse prevention post detoxification
| Lobbyist | Covered position, as disclosed |
|---|---|
| SARAH KUEHL EGGE | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.